BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.15 SEK | +1.62% |
|
+6.12% | +32.65% |
| Sales 2024 * | 63.6M 5.83M 486M | Sales 2025 * | 1.2B 110M 9.19B | Capitalization | 1.65B 152M 12.65B |
|---|---|---|---|---|---|
| Net income 2024 * | -964M -88.36M -7.37B | Net income 2025 * | 511M 46.84M 3.91B | EV / Sales 2024 * | 21 x |
| Net cash position 2024 * | 320M 29.29M 2.44B | Net cash position 2025 * | 1.49B 137M 11.42B | EV / Sales 2025 * | 0.13 x |
| P/E ratio 2024 * |
-6.4
x | P/E ratio 2025 * |
2.58
x | Employees | 109 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioInvent International AB
More press releases
| 1 day | +1.62% | ||
| 1 week | +6.12% | ||
| Current month | +47.94% | ||
| 1 month | +47.94% | ||
| 3 months | +53.54% | ||
| 6 months | +72.97% | ||
| Current year | +32.65% |
1 week
22.20
25.25
1 month
16.7625.25
Current year
15.0025.25
1 year
14.0029.90
3 years
14.0061.40
5 years
14.0063.00
10 years
14.00106.00
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Welschof
CEO | Chief Executive Officer | 63 | 01/18/01 |
Stefan Ericsson
DFI | Director of Finance/CFO | 61 | 01/98/01 |
Marie Moores
COO | Chief Operating Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | 01/18/01 |
Leonard Kruimer
CHM | Chairman | 66 | 12/16/12 |
Vincent Ossipow
BRD | Director/Board Member | 55 | 12/16/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 25.15 | +1.62% | 46,437 |
| 25/24/25 | 24.75 | +6.68% | 175,232 |
| 24/24/24 | 23.2 | -0.85% | 55,571 |
| 23/24/23 | 23.4 | +0.43% | 32,774 |
| 22/24/22 | 23.3 | -1.69% | 74,301 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotes
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
03/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
25.15
SEK
Average target price
83
SEK
Spread / Average Target
+230.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.65% | 151M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BINV Stock
